Safety and early response study of AVA6000 for solid tumors
Part of Cancer, Hormones & metabolism, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older) and sign the informed consent form
- You have a specific type of solid tumor that is “FAP positive” or matches certain cancer types listed, and it is advanced (not fully removable) and/or metastatic
- Your cancer must meet additional rules for your cancer type (for example, prior treatments you’ve had or haven’t had)
- You need recent measurable disease on scans and must be well enough for treatment (performance status 0–1)
- You must have usable blood counts, liver and kidney function, and your past treatment side effects must be mostly recovered
- You must be able to provide tumor tissue samples (about 10 slides) if a new or archived biopsy is feasible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Hear when a new Salivary Gland Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.